SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

A sharp AMP rally and surge in trading volume are driving attention, with traders debating whether the move signals a sustained reversal or another short-lived pump. Bullish holders also point to Flexas European expansion and broader stablecoin-payment adoption, while skeptics cite AMPs prolonged losses and question whether network activity will translate into token demand.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong second-quarter results and accelerating PAPZIMEOS sales are driving discussion, with traders pointing to the launchs commercial progress and the companys path toward cash-flow break-even. Many are bullish on the product and upcoming European and cancer-pipeline milestones, while others are frustrated by muted price action and debate short pressure and competition from INO-3107.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being tied to the launch of confidential perpetual futures powered by Hyperliquid, which traders say brings privacy to leveraged on-chain trading. The community is broadly bullish and cites strong momentum, though some warn the move may be overextended or vulnerable to a pullback.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FET is drawing attention after a recent rebound, with traders watching whether it can clear resistance and extend the move. The discussion links optimism to Fetch.ais autonomous-agent and decentralized-AI narrative, while skeptics cite underperformance versus other AI tokens and the risk that weakness in Bitcoin could reverse the gains.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Traders have linked Bitcoin Cashs sharp rally to CME futures access and a Grayscale filing, while technical breakout chatter has added to the attention. The community is divided over whether the move can resume, with bullish calls for a recovery alongside concerns about fading momentum and a deeper pullback.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

Repeated Sui mainnet outages and a network halt are driving concern about the blockchains reliability and weighing on sentiment. Some traders view the weakness as a buying opportunity, while others remain bearish until the network issues are addressed.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is drawing attention for its Apogee acquisition and strong momentum alongside a rotation into healthcare, while investors debate whether the deals pipeline potential justifies its cost. Much of the chatter also speculates that AbbVie could bid for SELLAS, but that takeover talk is unconfirmed.

Hecla Mining Co. engages in the provision of precious and base metals. It operates through the following segments: Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. The company was founded by Amasa B. Campbell, Patsy Clark, and John Finch on October 14, 1891 and is headquartered in Coeur d'Alene, ID.

Hecla Mining Co.

Hecla Mining Co

Rising silver prices and expectations that silver miners will catch up with the metal are driving attention to Hecla. Many traders are bullish on the precious-metals outlook, while others are frustrated that HL has lagged silver and point to volatility and resistance as reasons for caution.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific (APAC). Its brands include Abercrombie and Hollister. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

A strong Q2 report and raised full-year outlook sparked a sharp rally and talk of a short squeeze, with traders also pointing to buybacks and improving brand trends. The debate is whether the gains are sustainable, since a one-time tariff refund boosted results, while many bearish traders expect profit-taking after the run-up.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebecs payroll and payments expansionincluding reported early enterprise use on Stellarhas renewed interest in its real-world utility, but traders remain focused on whether adoption will translate into sustained token demand. The community is split between accumulating and staking for the long term and criticizing ZBCNs weak price action and volume despite its partnership announcements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial 

Equity

TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.


Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results...

Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference...

TriLink BioTechnologies Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap Capping Technology

TriLink BioTechnologies, LLC (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of...

TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale

TriLink, part of Maravai LifeSciences (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA...

This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio

This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio...

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility...

Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief...

Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm’s brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Maravai LifeSciences Holdings Inc - Ordinary Shares - Class A

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$7.60
Prev Close	$7.65
Open	$7.61
Dividend Yield	0.00%
50-Day Moving Average	$7.02
Beta	1.23
Avg. Volume	4.5M
PE Ratio	-14.29

52-Week High	$9.42
52-Week Low	$2.55
Market Capitalization	$1.97B
EPS (Annual)	-$0.9059
Price to Book	5.53
Revenue Per Employee	$426,995.40

Feed

News

Sentiment

Earnings

Fundamentals

Info

MRVI Fundamentals